Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSH | P09668 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489224 | 1.00 | LMNA (0.34) | LMNACHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6392087 | 1.00 | LMNA (0.34) | LMNACHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL489632 | 0.94 | GAA (0.39) | LMNAKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL2807972 | 0.93 | TSHR (0.35) | LMNACHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12311415 | 0.81 | CHRNB4 (0.38) | LMNACHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27929797 | 0.80 | ACHE (0.34) | LMNACHRM1HRH3KDM4EALDH1A1 | |
| SCHEMBL27892417 | 0.76 | ENO1 (0.34) | HRH3ALDH1A1GAAHPGDRECQL | |
| SCHEMBL261002 | 0.76 | GAA (0.32) | HRH3GAAHPGDRECQL | |
| SCHEMBL27517307 | 0.74 | HPGD (0.41) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL28780419 | 0.74 | POLB (0.33) | HRH3GAAHPGDRECQLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2015-01-08 | — | — | US | claimed |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2010-05-13 | — | — | US | claimed |
| EP-2152669-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | Cephalon, Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008137087-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | CEPHALON, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| EP-3889141-A1 | (R)-3-(4'-(2-(2-METHYLPYRROLIDIN-1-YL)ETHYL)BIPHENYL-4-YL)PROPANOIC ACID AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3309150-B1 | (R)-3-(4'-(2-(2-METHYLPYRROLIDIN-1-YL)ETHYL)BIPHENYL-4-YL)PROPANOIC ACID AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARM INC (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3309150-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2943473-B1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARM INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9365511-B2 | Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders | ARENA PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20150353488-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9186353-B2 | Treatment of osteoarthritis pain | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040133007-A1 | Process for preparing amine-substituted benzofurans | ABBOTT LABORATORIES | 2004-07-08 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-05-13 | — | — | US | disclosed |
| WO-2004024707-A2 | PROCESS FOR PREPARING AMINE TYPE SUBSTITUTED BENZOFURANS | ABBOTT LABORATORIES (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040054185-A1 | Process for preparing amine-substituted benzofurans | COWART MARLON D (US) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353488-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | HRH3, HRH4, HRH1 | LMNA 4821/4885CHRM4 64/4885CHRM5 39/4885 |
| US-20150011759-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | LMNA 4225/4885CHRM4 300/4885CHRM5 126/4885 |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | LMNA 4711/4885CHRM4 478/4885CHRM5 431/4885 |
| US-20040133007-A1 | Process for preparing amine-substituted benzofurans | HRH4, HRH2, HRH3 | LMNA 3918/4885CHRM4 200/4885CHRM5 355/4885 |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | HRH4, HRH3, HRH2 | LMNA 3286/4885CHRM4 95/4885CHRM5 184/4885 |
| US-20100121055-A1 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF | TPMT, SPR, QDPR | LMNA 4225/4885CHRM4 300/4885CHRM5 126/4885 |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | LMNA 3402/4885CHRM4 249/4885CHRM5 200/4885 |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | LMNA 3906/4885CHRM4 264/4885CHRM5 242/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | LMNA 3299/4885CHRM4 221/4885CHRM5 201/4885 |
| US-20040054185-A1 | Process for preparing amine-substituted benzofurans | HRH4, HRH2, HRH3 | LMNA 3918/4885CHRM4 200/4885CHRM5 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.